We are live on
!
Find out more
VM
VHCP Management Portfolio holdings
AUM
$93M
1-Year Est. Return
10.04%
This Fund
S&P 500
This Quarter
Est. Return
+24.4%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$434M
AUM Growth
+$70.8M
(+19%)
Cap. Flow
+$15M
Cap. Flow
% of AUM
3.45%
Top 10 Holdings %
Top 10 Hldgs %
86.36%
Holding
22
New
2
Increased
2
Reduced
–
Closed
3
Avg Time Held
3.7
quarters
Top 10 Avg Time Held
4.3
quarters
Top 20 Avg Time Held
3.7
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$14.8M |
| 2 |
Arcturus Therapeutics
ARCT
|
+$9.43M |
| 3 |
STML
Stemline Therapeutics, Inc.
STML
|
+$1.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Radius Health, Inc.
RDUS
|
+$9.08M |
| 2 |
NeuBase Therapeutics, Inc. Common Stock
NBSE
|
+$3.98M |
| 3 |
Viracta Therapeutics, Inc. Common Stock
VIRX
|
+$1.37M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.49% |
| 2 | Miscellaneous | 28.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
JUNO
1
DELISTED
Juno Therapeutics, Inc.
JUNO
| $97M | 22.32% |
1,749,999
| – | – |
2014 Q4
1 quarter
|
|
|
ANAC
2
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $68.2M | 15.7% |
1,178,474
| – | – |
2013 Q2
7 quarters
|
|
3
DELISTED
Adverum Biotechnologies
ADVM
| $56M | 12.9% |
138,274
| – | – |
2014 Q3
2 quarters
|
|
|
GWPH
4
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $28.4M | 6.54% |
311,853
| – | – |
2013 Q2
7 quarters
|
|
5
Coherus Oncology
CHRS
$165M
| $26M | 5.99% |
870,269
| – | – |
2014 Q4
1 quarter
|
|
6
Larimar Therapeutics
LRMR
$277M
| $21.4M | 4.94% |
45,123
| – | – |
2014 Q2
3 quarters
|
|
|
DYAX
7
DELISTED
DYAX CORPORATION
DYAX
| $16.8M | 3.86% |
1,000,659
| – | – |
2013 Q2
7 quarters
|
|
8
Heron Therapeutics
HRTX
$77.1M
| $15.9M | 3.67% |
1,095,734
| – | – |
2013 Q3
6 quarters
|
|
9
BioCryst Pharmaceuticals
BCRX
$2.18B
| $15.8M | 3.63% |
1,744,356
| – | – |
2013 Q2
7 quarters
|
|
|
10
Ascendis Pharma A/S
ASND
$15.1B
| $12.9M | 2.97% |
+811,152
| New | +$14.8M |
2015 Q1
0 quarters
|
|
|
AVDL
11
DELISTED
Avadel Pharmaceuticals
AVDL
| $8.99M | 2.07% |
500,000
| – | – |
2014 Q1
4 quarters
|
|
|
12
Arcturus Therapeutics
ARCT
$391M
| $8.45M | 1.94% |
+214,286
| New | +$9.43M |
2015 Q1
0 quarters
|
|
|
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
| $6.53M | 1.5% |
451,400
+95,000
| +27% | +$1.45M |
2014 Q3
2 quarters
|
|
14
TherapeuticsMD
TXMD
$23.8M
| $5.12M | 1.18% |
16,930
| – | – |
2013 Q4
5 quarters
|
|
15
Lipocine
LPCN
$14.2M
| $4.62M | 1.06% |
39,407
| – | – |
2014 Q2
3 quarters
|
|
|
ZSPH
16
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $4.21M | 0.97% |
100,000
| – | – |
2014 Q2
3 quarters
|
|
|
OCRX
17
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $3.31M | 0.76% |
703,730
| – | – |
2013 Q4
5 quarters
|
|
|
18
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| – | – |
-2,553
| Closed | -$1.37M | – |
|
|
19
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| – | – |
-1,193
| Closed | -$3.98M | – |
|
|
20
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-233,294
| Closed | -$9.08M | – |
|
Similar funds
QGI
KC
RSCM
ZC
TF
SAM
NA
NCIM
VHCP Management's Q1 2015 Portfolio in Review
As of Q1 2015, VHCP Management held 22 positions worth $434M, up 19% from $364M the previous quarter. Its ten largest holdings account for 86% of the portfolio.
VHCP Management deployed $15M of net new capital in Q1 2015, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Ascendis Pharma A/S: 811,152 shares worth $12.9M.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 75% a quarter earlier, followed by Miscellaneous.
On the sell side, the most notable exit was Radius Health, Inc., an estimated $9.08M sold.
- VHCP Management's largest Q1 2015 buy was Ascendis Pharma A/S: 811,152 shares worth $12.9M.
- VHCP Management added most to Stemline Therapeutics, Inc. in Q1 2015, an estimated $1.45M increase.
- VHCP Management fully exited Radius Health, Inc. in Q1 2015, selling an estimated $9.08M.
- VHCP Management's ten largest holdings make up 86% of its $434M portfolio in Q1 2015.
- VHCP Management opened 2 new positions and closed 3 in Q1 2015.
- VHCP Management's portfolio value rose 19% quarter-over-quarter to $434M.
Based on VHCP Management's 13F filing for Q1 2015, filed 14 May 2015.